Clinical Trials Browser

Laryngeal Diseases × Cetuximab × Head & Neck × Clear all

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Laryngeal Diseases

NCT02128906 2025-03-26

Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design

Phase 2 Recruiting

120 enrolled

Head & Neck

Carcinoma, Squamous Cell, Laryngeal Diseases

NCT01884259 2022-05-26

HNO-2

Phase 2 Completed

100 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Laryngeal Diseases

NCT01326923 2020-10-09

Induction Chemo Then Concurrent Chemoradiotherapy With Cetuximab in Locally Advanced Head and Neck Squamous Cell Cancer

Phase 2 Terminated

7 enrolled 5 charts

Head & Neck

Laryngeal Diseases

NCT02205398 2019-01-22

Study of Safety and Efficacy of INC280 and Cetuximab, in Adult c-MET Positive mCRC and HNSCC Patients After Progression on Cetuximab or Panitumumab Therapy

Phase 1 Terminated

13 enrolled

GastrointestinalHead & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Laryngeal Diseases, Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT01540682 2018-08-29

MLN8237 in Head and Neck Cancer

Phase 1 Completed

9 enrolled

Head & Neck

Head and Neck Neoplasms, Laryngeal Diseases

NCT01057589 2013-09-18

A Study for Patients With Recurrent or Metastatic Squamous Cell Head and Neck Cancer

Phase 2 Completed

66 enrolled 11 charts

Head & Neck

Head and Neck Neoplasms, Laryngeal Diseases, Thyroid Diseases

NCT01427205 2013-04-05

Phase II Study of Cetuximab With or Without OSI-906 in Head and Neck Squamous Cell Carcinoma (HNSCC)

Phase 2 Withdrawn

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Laryngeal Diseases, Neoplasm Metastasis, Recurrence

Clinical Trials

INTERLINK-1

Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design

HNO-2

Induction Chemo Then Concurrent Chemoradiotherapy With Cetuximab in Locally Advanced Head and Neck Squamous Cell Cancer

Study of Safety and Efficacy of INC280 and Cetuximab, in Adult c-MET Positive mCRC and HNSCC Patients After Progression on Cetuximab or Panitumumab Therapy

MLN8237 in Head and Neck Cancer

A Study for Patients With Recurrent or Metastatic Squamous Cell Head and Neck Cancer

Phase II Study of Cetuximab With or Without OSI-906 in Head and Neck Squamous Cell Carcinoma (HNSCC)